Clinical trials
Lung Squamous Cell Carcinoma clinical trials
Below are recruiting lung squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 583 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07090317RecruitingPhase 2
Testing Two Immunotherapy Drugs for Advanced Head and Neck Cancer
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT07317609RecruitingPhase 1
Immunotherapy plus chemo before endoscopic resection for esophageal cancer
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07385001RecruitingPhase 1/Phase 2
Ivonescimab with chemotherapy before surgery for esophageal cancer
This trial tests a new drug called Ivonescimab (AK112) combined with two chemotherapy drugs (Abraxane and cisplatin) given before surgery for esophageal cancer. The goal is to see if this combination can shrink tumors and improve surgery outcomes for patients with locally advanced disease.
Xi'an, ShannxiAges 18–75 - NCT07457528RecruitingPhase 2
Chemo, radiation, and immune therapy before surgery for esophageal cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT04789681RecruitingPhase 2
Canakinumab to prevent lung cancer from persistent lung nodules
This trial tests canakinumab to lower the risk of lung cancer growing from persistent lung nodules seen on CT scans. It may help people at higher risk who have either never had lung cancer or had early lung cancer treated in the past.
Houston, TexasAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT05800223RecruitingPhase 3
Armatinib with or without brain radiation for EGFR lung cancer
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT04728724RecruitingPhase 2
Check immune treatment before surgery for stage III lung cancer
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
ShanghaiAges 18–75 - NCT04977791Recruiting
Study how drug resistance develops in lung cancer immunotherapy
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05104788RecruitingPhase 2
Icotinib plus chemotherapy before surgery for EGFR lung cancer
This trial studies how well a targeted medicine (icotinib) combined with chemotherapy works before surgery for certain EGFR-mutated lung adenocarcinoma. The goal is to shrink or control the tumor and make surgery more effective.
BeijingAges 18–75 - NCT05742607RecruitingPhase 2
Durvalumab plus IPH5201 before lung surgery for early cancer
This phase 2 study tests durvalumab plus IPH5201 given before surgery to improve outcomes for people with resectable non-small cell lung cancer. It aims to shrink or control the cancer and make surgery more effective, using information about specific tumor markers like PD-L1.
St. Petersburg, FloridaAges 18 years+ - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06352008RecruitingPhase 2
Anlotinib for lung cancer patients with incomplete response after chemo-immunotherapy
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
TianjinAges 18 years+ - NCT06406608Recruiting
Personalized drug test for drug-resistant lung cancer
This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.
Zhengzhou, HenanAges 18–75 - NCT06476093Recruiting
Radiation plus anlotinib for lung cancer brain spread
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
Lianyungang, JiangsuAges 18–80 - NCT06734182RecruitingPhase 2
Targeted therapy plus chemo before surgery for HER2-mutant lung cancer
This study tests a combination of two targeted drugs (envafolimab and disitamab vedotin) plus chemotherapy (carboplatin) given before surgery for lung cancer that has a HER2 mutation. The goal is to see if this can shrink the tumor and improve outcomes.
GuangzhouAges 18–75 - NCT06800339RecruitingPhase 1
Immunotherapy and radiation before surgery for lung cancer
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
Baltimore, MarylandAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+
Hear when a new Lung Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung squamous cell carcinoma?
- Yes. Clin2 currently lists 583 recruiting lung squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.